Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Sells 6,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at $3,647,966. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Tina Marriott also recently made the following trade(s):

• On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00.
• On Thursday, July 25th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.13, for a total transaction of $48,780.00.

Recursion Pharmaceuticals Stock Down 6.4 %

RXRX stock opened at $6.17 on Wednesday. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74. The company’s 50 day simple moving average is $6.95 and its 200-day simple moving average is $8.12. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The firm has a market capitalization of $1.73 billion, a P/E ratio of -3.86 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. During the same quarter in the prior year, the firm earned ($0.38) EPS. The firm’s revenue was up 30.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC cut their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.40.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Ghisallo Capital Management LLC acquired a new position in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $8,250,000. Perceptive Advisors LLC acquired a new position in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $5,769,000. Algert Global LLC acquired a new position in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $129,000. Scientech Research LLC acquired a new position in Recursion Pharmaceuticals in the 2nd quarter valued at approximately $1,052,000. Finally, The Manufacturers Life Insurance Company increased its stake in Recursion Pharmaceuticals by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company’s stock valued at $837,000 after buying an additional 27,440 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.